California firm takes cannabinoid research personally

by Invesbrain Tuesday, July 18, 2017
Print This Article

California firm looks to Israel for personalized cannabinoid approach

The news magazine ISRAEL21c reports a U.S. biopharma company is teaming up with an Israeli counterpart to forward the use of cannabinoids in the field of personalized medicine.

California-based CURE Pharmaceutical recently signed a memorandum of understanding with Therapix Biosciences of Tel Aviv. The “research collaboration” will be done in conjunction with the eight hospitals and medical centres of Israel’s Assuta Medical Centers.

Therapix’s lead compound THX-TS01 is currently in phase 2 clinical trials to treat Tourette’s syndrome. It hopes to begin a Phase 1 clinical trial for another compound, THX-ULD01, for the treatment of mild cognitive impairment.

Both compounds employ an “FDA-approved synthetic THC.”

Therapix is also developing new cannabinoid delivery technologies including nasal and sublingual (under the tongue) methods.

(READ MORE)

CMAJ commentary argues for two-stream cannabis system

Arguing ‘recreational cannabis and cannabinoid-based drugs (including medical cannabis) are not equivalent,’ the authors of a commentary in the Canadian Medical Association Journal say Canada should continue with a separate medical cannabis stream after legalization.

In a report by EurekAlert!, Elizabeth Cairns and Dr. Melanie Kelly of Dalhousie University’s Department of Pharmacology, write that “(without) a program that supports medical use, patients may lose access to treatments that the Federal Court of Canada has deemed appropriate, which fosters safe and appropriate use."

The Task Force on Cannabis Legalization and Regulation also recommended a two-streamed system.
According to the EurekAlert! report, “the authors suggest that a medical stream for cannabis and cannabinoids would reduce risk to patients, provide incentives for research into the therapeutic effects of cannabinoids, and provide educational resources for health care practitioners on the latest advances in cannabinoid research.”

(READ MORE)

U.S.-German-Israeli deal links cancer diagnostics with cannabinoids

MMJ Reporter writes an American cannabinoid firm with an R&D foothold in Israel is teaming up with a German “world pioneer in cancer diagnostics.”

Cannabics Pharmaceuticals Inc. recently agreed to become “the exclusive international provider unit” of SIMFO GmbH’s Circulating Tumour Cell (CTC) diagnostics to people suffering with cancer and being treated with CBDs.

SIMFO previously initiated preclinical trials into CBDs and drug development with Cannabics’ cannabinoid formulations.

Cannabics’ R&D facility is “concentrated” in Israel.

(READ MORE)

Data on CBD analogue to be presented at neuroscience meeting

Stockhouse reports Califonia-based NEMUS Bioscience is set to present research on its CBD analogue at the Annual Meeting of the Society of Neuroscience this November.

The data, compiled by NEMUS’ R&D partner the University of Mississippi “will show the superiority of the NEMUS proprietary analogue of CBD, NB2222, versus plant-derived CBD in ameliorating pain in a validated mouse (murine) model of chemotherapy-induced peripheral neuropathy using an opioid as an active comparator.”

The firm will also present data on the anti-addictive potential of NB2222.

"We have been able to demonstrate that NB2222 was able to deliver analgesia comparable to morphine, which has been implicated in the current global opioid abuse epidemic. The research team then moved to the next step using a validated animal model of addiction to opioids to assess the anti-abuse potential of NB2222 as a therapeutic. We look forward to presenting the data this fall," said Dr. Kenneth Sufka, research professor with the National Center for Natural Products Research at UM.

(READ MORE)

Has A Big Bear Market Rally Just Finished ? 2019-03-23 Weekly Market Roundup

World Charts Look Risky Outside Bars Suggest Reversal Commodities Under Fire Timing on the Copper and Steel charts is Unnerving Energy-related ETFs and Stocks have Huge Caution Signs Watching to see if Gold is the Next Bullish Move (expecting a huge move) Continuin...

Florida Boxing Commission May Change Pot Rules For MMA

Cannabis progress continues in Florida with professional MMA fighters, the newest beneficiaries of the state’s rapidly changing views on medical marijuana and CBD. According to reports from journalist Steven Marrocco of MMAJunkie, the UFC’s Vice President of Athlete Health ...

Redefine Your Cannabis Consumption With Spark

As the cannabis industry evolves, more options have become available for consumers to enjoy their herb. Unfortunately, many of them still raise some concerns. Whether you’re hesitant to fork over the money for an expensive concentrate that contains who knows what or you have a...

Caribbean Region Emerges as Next Big Cannabis Marketplace

With regional leader Jamaica having recently exported its first cannabis products to Canada, other island nations of the Caribbean are readying their own proposals for either decriminalization, a legal medical market for cannabis, or both.  After Jamaica, Saint Vincent & the Gr...

March 22, 2019

The International Association of Insurance Supervisors has announced: The CSFWG will host an ICS Stakeholder Meeting in Orlando on 10 April. The stakeholder meeting is intended to provide a forum for constructive feedback on ICS Version 2.0. Stakeholders who wish to provide pres...

Advertisers Are Watching: What Kind of Marijuana User Are You?

The cannabis industry is trying to figure out who you are. More specifically, the companies that make up this multibillion-dollar business sector want to get inside the heads of the consumer so they can squeeze as much money from us as possible in the coming years. But there’s...

OneSoft Solutions has an upside of 122 per cent, says Beacon Securities

Beacon Securities analyst Gabriel Leung has initiated coverage of pipeline data company OneSoft Solutions (OneSoft Solutions Stock Quote, Chart TSXV:OSS), saying that its subsidiary OneBridge Solutions is addressing a key risk in the oil and gas sector. Edmonton-based OneSoft op...

Saskatchewan Budget: Government Actions Return Province to Balance

The Conference Board of Canada Economist Daniel Lam offers insights on Saskatchewan’s 2019 Budget: Quote “Following two years of recession in 2015 and 2016, that drove the province deep into the red, Saskatchewan drastically increased taxes and announced a stringent spending...

How to use ETFs in your child’s RESP

Q. Several years ago, an advisor recommended I hold a Canadian dividend ETF in an RESP for my son. Would this still be a good approach for someone just starting an RESP for their baby, or is there a better alternative, given the increasing number of ETF options? – Pete in Hali...

Weekly Market Review & Outlook - Crosscurrents, Undercurrents and Weight of the Evidence

Bigger Downtrends or Simply Resting? Bank ETFs Fail at 200-day SMAs Small-cap Indexes Fail near Retracements Oil Nears Potential Reversal Zone Focus on the True Leaders S&P 500 Maintains Uptrend Index Breadth Table Remains Bullish Sector Breadth Table is More Mixed Staples, Utili...